文献速递骨质疏松与代谢性骨病创伤骨科

PTH1受体激动剂降低骨折风险:系统评价与网络Meta分析

PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.
PubMed 文献 · Osteoporos Int · 2025-03-06

该系统评价与网络Meta分析检索了截至2024年5月的Medline、Embase和Cochrane数据库,纳入17项研究(11项随机对照试验和6项真实世界证据研究),比较特立帕肽和阿巴洛帕肽与其他骨质疏松治疗对椎体、非椎体、髋部或全部骨折的疗效及安全性。结果显示两者均能有效降低椎体和非椎体骨折风险,阿巴洛帕肽在非椎体骨折(OR 0.87,95%CI 0.80-0.95)和髋部骨折(OR 0.81,95%CI 0.71-0.93)方面优于特立帕肽,且两者安全性与其他治疗相当,无心血管风险增加。

要点

  • 阿巴洛帕肽较特立帕肽降低非椎体骨折风险(OR 0.87,95%CI 0.80-0.95)。
  • 阿巴洛帕肽较特立帕肽降低髋部骨折风险(OR 0.81,95%CI 0.71-0.93)。
  • 两种PTH1受体激动剂安全性与其他骨质疏松治疗相当,未增加心血管风险。

核心结论

  • PTH1受体激动剂可有效降低骨折风险,阿巴洛帕肽在非椎体骨折和髋部骨折方面较特立帕肽具有更优获益,两者安全性可接受。

研究设计与样本

  • 系统评价与网络Meta分析,检索Medline、Embase和Cochrane数据库截至2024年5月,纳入报告椎体、非椎体、髋部或全部骨折减少为主要终点的随机对照试验和真实世界证据研究,共纳入17项研究(11项随机对照试验,6项真实世界证据研究)。

主要发现

  • 在所有与安慰剂比较的配对Meta分析中,特立帕肽和阿巴洛帕肽均能有效降低椎体骨折和非椎体骨折。
  • 阿巴洛帕肽在非椎体骨折(OR 0.87,95%CI 0.80-0.95)和髋部骨折(OR 0.81,95%CI 0.71-0.93)方面优于特立帕肽。
  • 在网络Meta分析模型中,特立帕肽和阿巴洛帕肽在降低椎体骨折方面优于安慰剂、雷洛昔芬和降钙素,特立帕肽还优于地舒单抗和利塞膦酸。
  • 对于非椎体骨折,阿巴洛帕肽优于其他任何治疗,而特立帕肽仅优于阿仑膦酸或安慰剂。
  • PTH1类似物在降低全部骨折方面优于安慰剂,但髋部骨折风险未见差异;阿巴洛帕肽和特立帕肽与其他骨质疏松治疗安全性相当,未增加心血管风险。

关键数值与推荐

  • 阿巴洛帕肽对比特立帕肽的非椎体骨折OR为0.87(95%CI 0.80-0.95),髋部骨折OR为0.81(95%CI 0.71-0.93)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Osteoporosis, defined by reduced bone mineral density and macro- and micro-architectural degradation, leads to increased fracture risk, particularly in aging populations. While randomized controlled trials (RCTs) demonstrate that PTH1 receptor agonists, teriparatide and abaloparatide, are effective at reducing fracture risk, real-world evidence (RWE) remains sparse. This study reviews and compares the anti-fracture efficacy of these agents, against each other and against other osteoporosis treatments using both RCTs and RWE. We systematically searched Medline, Embase, and Cochrane up to May 2024, focusing on RCTs and RWE studies reporting reduction in vertebral, non-vertebral, hip, or all fractures as primary endpoint. A network meta-analysis (NMA) was conducted, first through pairwise meta-analyses of teriparatide versus abaloparatide, then a Bayesian NMA comparing each to other treatments. Safety assessments included adverse events classified by MedDRA, with a particular attention to hypercalcemia and cardiac events. Seventeen studies (11 RCTs, 6 RWE) met inclusion criteria. Teriparatide and abaloparatide were effective in reducing vertebral and non-vertebral fractures in all pairwise meta-analyses versus placebo. Abaloparatide showed an advantage over teriparatide for non-vertebral fractures (OR: 0.87, 95% CI: 0.80-0.95) and hip fractures (OR: 0.81, 95% CI: 0.71-0.93). In the NMA model, teriparatide and abaloparatide were superior to placebo, raloxifene, and calcitonin in reducing vertebral fracture while teriparatide was further superior to denosumab and risedronate. For non-vertebral fracture, abaloparatide was better than any other treatment while teriparatide was only superior to alendronate or placebo. PTH1 analogs were better than placebo at reducing all fractures while no difference was observed for the risk of hip fracture. Both abaloparatide and teriparatide demonstrate comparable safety to other osteoporosis treatments, with no increased cardiovascular risk. This review highlights that PTH1 receptor agonists effectively reduce fracture risk, with abaloparatide offering enhanced benefits for non-vertebral and hip fractures compared to teriparatide. Both agents exhibit acceptable safety profiles, suggesting their valuable role in managing osteoporosis, particularly for high-risk patients.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Beaudart C, Veronese N, Douxfils J, et al. PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis. Osteoporos Int. 2025. PMID: 40047881. doi:10.1007/s00198-025-07440-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。